{"id":688645,"date":"2022-09-26T07:17:20","date_gmt":"2022-09-26T11:17:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/"},"modified":"2022-09-26T07:17:20","modified_gmt":"2022-09-26T11:17:20","slug":"regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/","title":{"rendered":"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Company to host conference call on <span class=\"xn-chron\">Monday, October 3<\/span><sup>rd<\/sup> at <span class=\"xn-chron\">8:30 a.m. ET<\/span> to discuss new, interim data from the ongoing Phase II AAVIATE<sup>\u00ae<\/sup> trial<\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">ROCKVILLE, Md.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 26, 2022<\/span><\/span> \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held <span class=\"xn-chron\">September 30-October 3, 2022<\/span> in <span class=\"xn-location\">Chicago, IL.<\/span> The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions.<\/p>\n<p>Presentations include:<\/p>\n<p>\n        <b>Title: <\/b>Subretinal RGX-314 Gene Therapy: Phase I\/IIa Long-Term Follow-Up Results up to 4 Years<br \/><b>Presenter: <\/b><span class=\"xn-person\">Peter A. Campochiaro<\/span>, M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, <span class=\"xn-org\">Johns Hopkins University School of Medicine<\/span><br \/><b>Date\/Time: <\/b><span class=\"xn-chron\">Saturday, October 1, 2022<\/span>, <span class=\"xn-chron\">2:25 CDT<\/span><\/p>\n<p>\n        <b>Title: <\/b>Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: The Phase 2 ALTITUDE Study (encore)<br \/><b>Presenter: <\/b><span class=\"xn-person\">Arshad Khanani M.D<\/span>., M.A, Managing Partner, Director of Clinical Research, Sierra Eye Associates, Clinical Associate Professor, <span class=\"xn-org\">University of Nevada, Reno<\/span> School of Medicine<br \/><b>Date\/Time:<\/b>\u00a0Sunday, October 2, 2022, <span class=\"xn-chron\">3:45 CDT<\/span><\/p>\n<p>On <span class=\"xn-chron\">Monday, October 3<\/span> at <span class=\"xn-chron\">8:30 a.m. ET<\/span>, REGENXBIO also plans to host a conference call to provide a new, interim update from the ongoing Phase II AAVIATE<sup>\u00ae<\/sup> trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery. Details for the call will follow.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>About REGENXBIO Inc.<\/b>\n      <\/div>\n<p>REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO&#8217;s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a &#8220;5x&#8217;25&#8221; strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Dana Cormack<\/span><br \/>\n        <br \/>Corporate Communications<br \/><a href=\"mailto:dcormack@regenxbio.com\" target=\"_blank\" rel=\"nofollow noopener\">dcormack@regenxbio.com<\/a>\u00a0<\/p>\n<p>Investors:<br \/><span class=\"xn-person\">Chris Brinzey<\/span><br \/>ICR Westwicke<br \/>339-970-2843<br \/><a href=\"mailto:chris.brinzey@westwicke.com\" target=\"_blank\" rel=\"nofollow noopener\">chris.brinzey@westwicke.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2895\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg\" title=\"(PRNewsfoto\/REGENXBIO Inc.)\" alt=\"(PRNewsfoto\/REGENXBIO Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH83425&amp;sd=2022-09-26\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting-301632748.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting-301632748.html<\/a><\/p>\n<p>SOURCE  REGENXBIO Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH83425&amp;Transmission_Id=202209260705PR_NEWS_USPR_____PH83425&amp;DateId=20220926\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Company to host conference call on Monday, October 3rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE\u00ae trial ROCKVILLE, Md. , Sept. 26, 2022 \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions. Presentations include: Title: Subretinal RGX-314 Gene Therapy: Phase I\/IIa Long-Term Follow-Up Results up to 4 YearsPresenter: Peter A. Campochiaro, M.D., Director, Retinal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688645","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Company to host conference call on Monday, October 3rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE\u00ae trial ROCKVILLE, Md. , Sept. 26, 2022 \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions. Presentations include: Title: Subretinal RGX-314 Gene Therapy: Phase I\/IIa Long-Term Follow-Up Results up to 4 YearsPresenter: Peter A. Campochiaro, M.D., Director, Retinal &hellip; Continue reading &quot;REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T11:17:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting\",\"datePublished\":\"2022-09-26T11:17:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/\"},\"wordCount\":383,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/\",\"name\":\"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"datePublished\":\"2022-09-26T11:17:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - Market Newsdesk","og_description":"PR Newswire Company to host conference call on Monday, October 3rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE\u00ae trial ROCKVILLE, Md. , Sept. 26, 2022 \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions. Presentations include: Title: Subretinal RGX-314 Gene Therapy: Phase I\/IIa Long-Term Follow-Up Results up to 4 YearsPresenter: Peter A. Campochiaro, M.D., Director, Retinal &hellip; Continue reading \"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-26T11:17:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting","datePublished":"2022-09-26T11:17:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/"},"wordCount":383,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/","name":"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","datePublished":"2022-09-26T11:17:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688645"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688645\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}